Table 5.
Class | Properties | 3-O-(galloylglucoside) | 4-O-(galloylglucoside) | Epicatechin gallate | Remdesivir | Dexamethasone |
---|---|---|---|---|---|---|
Absorption | Caco-2 permeability | Negative | Negative | Negative | Negative | Positive |
Human intestinal absorption | Negative | Negative | Positive | Positive | Positive | |
Human oral bioavailability | Negative | Negative | Negative | Negative | Negative | |
Pgp-inhibitor | Negative | Negative | Negative | Positive | Negative | |
Pgp-substrate | Negative | Negative | Negative | Positive | Positive | |
Distribution | PPB (plasma protein binding) | Moderately high (95.31%) | Moderately high (94.27%) | High (102.20%) | Very high (118.2%) | High (100%) |
BBB (Blood–brain barrier) | Negative | Negative | Negative | Positive | Positive | |
Metabolism | CYP450 1A2 inhibition | Negative | Negative | Negative | Negative | Negative |
CYP450 3A4 inhibition | Negative | Negative | Negative | Negative | Negative | |
CYP450 3A4 substrate | Negative | Negative | Positive | Positive | Positive | |
CYP450 2C9 inhibition | Negative | Negative | Negative | Negative | Negative | |
CYP450 2C9 substrate | Negative | Negative | Negative | Negative | Negative | |
CYP450 2C19 inhibition | Negative | Negative | Negative | Negative | Negative | |
CYP450 2D6 inhibition | Negative | Negative | Negative | Negative | Negative | |
CYP450 2D6 substrate | Negative | Negative | Negative | Negative | Negative | |
CYP inhibitory promiscuity | Negative | Negative | Negative | Negative | Negative | |
UGT catalyzed | Positive | Positive | Negative | Negative | Positive | |
Sub-cellular localization | Mitochondria | Mitochondria | Mitochondria | Lysosomes | Mitochondria | |
Toxicity | Acute oral toxicity (kg/mol) | 2.5726 | 2.5958 | 2.3672 | 3.4279 | 2.486 |
Ames mutagenicity | Negative | Negative | Negative | Negative | Negative | |
Carcinogens | Negative | Negative | Negative | Negative | Negative | |
Human hepatotoxicity | Positive | Negative | Positive | Positive | Negative |